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Abstract
Background: Deletion of 15q21q22 is a rare chromosomal anomaly. To date, there have been
nine reports describing ten individuals with different segmental losses involving 15q21 and 15q22.
Many of these individuals have common features of growth retardation, hypotonia and moderate
to severe mental retardation. Congenital heart disease has been described in three individuals with
interstitial deletion involving this region of chromosome 15.
Case presentation: We report a child with coarctation of the aorta, partial agenesis of corpus
callosum and mild to moderate developmental delay, with a de novo deletion of 15q21.1q22.2,
detected by the array Comparative Genomic Hybridization (CGH). We utilized chromosome 15-
specific microarray-based CGH to define the chromosomal breakpoints in this patient.
Conclusion: This is the first description of mapping of an interstitial deletion involving the
chromosome 15q21q22 segment using the chromosome 15-specific array-CGH. The report also
expands the spectrum of clinical phenotype associated with 15q21q22 deletion.
Background
Interstitial deletion of chromosome 15q21q22 is an infre-
quently described chromosomal abnormality. To date,
there have been only ten individuals reported, nine with
variable deletions involving 15q21 [1-9] and one individ-
ual with more distal deletion encompassing the
15q22q25 region [5]. All patients described have moder-
ate to severe mental retardation. The four patients
described by Yip et al. [1], Fryns et al. [2], Martin et al. [3]
and Liehr et al. [4] have comparable cytogenetic break-
points and share common features, including beaked
nose, thin upper lip, and mental retardation. Congenital
heart disease was described in one patient with 15q21q24
deletion [5] and two patients with interstitial deletion of
chromosome 15q15q21 and 15q15q22 respectively [7,8].
Here, we describe an individual with deletion of
15q21.1q22.2, coarctation of the aorta and mild to mod-
erate developmental delay.
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The proband was a 36-week product of a twin pregnancy,
born to a 39-year old female. Pregnancy was achieved by
in vitro fertilization secondary to mother's history of
endometriosis. His birth weight was 2.44 kg, (40th percen-
tile), length was 47 cm (50th percentile), and head circum-
ference was 34.5 cm (90th percentile). A cardiac murmur
was noted soon after birth. An echocardiogram revealed
severe juxtaductal aortic coarctation with near aortic arch
interruption. He had a moderately dilated main pulmo-
nary artery and branch arteries, severe septal hypertrophy,
moderately depressed biventricular systolic function, biv-
entricular hyprertrophy, and bicommissural aortic valve.
He was also noted to have high arched palate, microg-
nathia, and low set ears with thickened helices. He had
fair suck, normal muscle tone and strength. Renal ultra-
sound showed decreased corticomedullary differentia-
tion, bifid right renal pelvis and moderate pelviectasis.
Head ultrasound showed partial agenesis of corpus callo-
sum (see Additional file 1). He underwent surgery for jux-
taductal aortic coarctation with end-to-end anastomosis
and PDA ligation. At one year of age, his weight was 10.5
kg (50th percentile), length was 77.5 cm (80th percentile)
and head circumference was 48.8 cm (95th percentile). He
had prominent forehead, midface hypoplasia, thinned
lateral eyebrows, intermittent strabismus, low set ears
with thickened helices, carp-shaped mouth and retrog-
nathia (Figure 1). He started walking independently at 16
months of age. His renal ultrasound was subsequently
repeated and was found to be normal. He had a brief sei-
zure episode at 16 months of age. Since then, he has been
treated with Valproic acid and the seizures have not
recurred. MRI scan of the brain following the seizure epi-
sode showed diffuse delay in myelination and partial
agenesis of corpus callosum. EEG showed generalized par-
oxysmal activity with high voltage slow waves and some
short spikes.
At a chronological age of 48 months, he is in a regular
classroom with children, a year younger than him. He is
able to throw and catch a ball, march to a song, and use a
spoon. He is not yet able to walk down stairs using alter-
nating feet. He is able to name body parts, identify some
shapes. He speaks in simple phrases, understands prepo-
sitions, and can follow simple commands. He receives
speech therapy for his speech/language delays. His current
level of functioning was evaluated based on teacher's
assessment of his development across the domains of
gross motor, fine motor, social/emotional, speech/lan-
guage, and functional skills. Using the Learn and Play
questionnaire, his level of functioning was broadly
assessed between 23–34 month level, depending upon
the specific task, reflecting mild delays in some and mod-
erate delays in other areas. His motor skills are estimated
to fall at the 25–26 month-old level, reflecting mild to
moderate delays in this area. His language skills are
slightly more delayed, falling at approximately the 23–24
month level, reflecting moderate delays. Cognitively, he is
able to count from 1–10 in a stable sequence (a 34-month
skill).
Cytogenetics, Comparative genomic hybridization and 
FISH analyses
Giemsa-banded chromosome analysis was performed
according to standard procedures on peripheral blood
lymphocytes. Twenty metaphases were examined at the
550-band level. Further delineation of the size and
boundaries of the deletion was carried out by genomic
array-based comparative genomic hybridization (CGH)
and FISH. For array CGH, we utilized a high-resolution
chromosome 15-specific BAC array developed in our lab-
oratory that included 106 BAC clones across 15q. The
highest density of clones is across the ~10-Mb 15q11-q14
interval encompassing the common Prader-Willi/Angel-
man syndrome critical region including the common
deletion/duplication breakpoints. Therefore a resolution
of greater than 1 clone per megabase for 15q11-q14 and
less than 1 clone per megabase for 15q14-qter was
achieved in this version of the chromosome 15 array.
Additionally the array included 38 clones specific for the
subtelomeric region of 41 clinically relevant telomeres for
chromosomes 1 to 22, including 12 clones for chromo-
somes X and 6 clones for Y chromosome. All clones were
selected based on physical maps represented in build 34
Proband at 20 months of ageFigure 1
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protocols for DNA preparation, labeling and hybridiza-
tion were followed as described previously [11]. A single
normal male DNA was used as reference control for anal-
ysis of the proband. All array-CGH experiments included
dye reversal and two array hybridizations to obtain an
accurate ratio [11]. After quantification and normaliza-
tion of data for each clone on each of the duplicate arrays,
the data from dye-reversed pairs were combined, and
inferences were made according to a clone-by-clone clas-
sification procedure to determine the gain/loss status of
each clone for each subject. The clone by clone classifica-
tion procedure is similar to the independent clone proce-
dure published previously [11]. From a number of test
experiments, the overall mean across all clones for the
gain state was +0.22, for the loss state -0.34, and for the
no-change state -0.04 (Figure 2). These values were set as
approximate values for predicting a loss or gain for a
Chromosome 15 array Comparative genomic hybridization (CGH) analysis and partial karyotype of the caseFigure 2
Chromosome 15 array Comparative genomic hybridization (CGH) analysis and partial karyotype of the case. 
(A) The log2 ratio plots representing array-CGH analysis using the chromosome 15-BAC microarray. Raw and Normalized 
data are shown in a clone-by-clone order for both dye-reversal experiments; the combined ratio plot designates loss, gain or 
normal value for every clone. The ordering of clones (top to bottom) is for chromosome 15 centromere to telomere, followed 
by all other autosomes and chromosomes X and Y. The overall mean across all clones for the gain state was +0.22, for the loss 
state -0.34, and for the no-change state -0.04. These values were set as approximate values for predicting a loss or gain for a 
clone. A loss value is seen for five non-overlapping clones. The clones listed in blue are deleted; the adjacent clones listed in 
black are not deleted. Clone RP11-353B9 (italicized) was not an arrayed clone but was included for FISH analysis as it was 
immediately proximal to the deletion boundary. The meagabase position of clones is indicated alongside the clone number. (B) 
Ideogram of chromosome 15 with demarcation (red box) of the CGH-predicted breakpoints with reference to cytogenetic 
bands. Partial karyotype, showing normal and deleted chromosome 15, with an apparent interstitial deletion of 15q21.2q22.1.Page 3 of 6
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that mapped within, proximal and distal to the deletion
boundaries predicted by the array CGH. These included
RP11-485O10 [GenBank: AC090846] and RP11-353B9
[GenBank:AC018927] proximal to and RP11-231A23
[GenBank:AC023190] distal to the deletion interval pre-
dicted by CGH (RP11-353B9 was not included in the
array but was used for narrowing down the interval by
FISH only) and clones RP11-105D1 [Gen-
Bank:AC022407], RP11-23N2 [GenBank:AC025917],
RP11-215J7 [GenBank:AC009559], RP11-323F24 [Gen-
Bank:AC010999] and RP11-50C13 [Gen-
Bank:AC018904] within the interval (Figures 2 and 3).
Additionally, FISH with RP11-69G7 [Gen-
Bank:AC087612] encompassing α-tropomyosin gene was
carried out prior to the array-CGH analysis as this was an
important candidate gene for the cardiac phenotype in the
proband and was located within the broader interval as
estimated by G-banding and karyotype. FISH analyses
were carried out as previously described [12]. At least ten
metaphase preparations were scored for each hybridiza-
tion.
Results
G-band analysis of a peripheral blood sample revealed an
abnormal male karyotype: 46, XY, del(15)(q21.2q22.1).
Parental chromosomes were normal. Deletion at 22q11
(DiGeorge syndrome critical region) was excluded by
FISH. Array CGH revealed an interstitial deletion with loss
of 5 non-overlapping clones across 15q21.1-q22.2 (RP11-
Fluorescence in situ hybridization (FISH) of 15q21.1q22.2 region using BAC probesigure 3
Fluorescence in situ hybridization (FISH) of 15q21.1q22.2 region using BAC probes. (A) Hybridization with clones 
RP11-231A23 (green; distal to the deletion interval) and RP11-105D1 (red) showing deletion of one copy of RP11-105D1. (B) 
Deletion of one copy of RP11-23N2 (red) hybridized with centromeric control probe (green). (C) Hybridization with RP11-
50C13 (green) and RP11-485O10 (red; proximal to the deletion boundary) showing deletion of one copy of RP11-50C13. (D) 
Hybridization with RP11-69G7 (red) encompassing α-tropomyosin gene, shows intact alleles on both chromosomes.Page 4 of 6
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The proximal boundary was telomeric to clone RP11-
353B9 and distal boundary was centromeric to RP11-
231A23. This included the interval between 15q21.1 to
15q22.2 and spanned a genomic segment of at least 7.54
Mb (Figure 2). FISH analysis using clones within and
flanking the boundary confirmed the size and extent of
the deletion (Figure 3). All of the five clones predicted by
CGH to be within the deleted interval were deleted from
one copy of the patient's chromosome 15. Additional
FISH with RP11-69G7 that contains TPM1, the α-tropo-
myosin gene showed two hybridization signals, confirm-
ing the presence of both copies of the gene in this patient.
Discussion
Deletion of 15q21 is an infrequently described chromo-
somal abnormality. Of the ten reported cases, many have
common features of beaked nose, hypoplastic alae nasi,
thin upper lip, truncal obesity, growth retardation, hypo-
tonia and moderate to severe mental retardation [[1-3]]
(see Additional file 1). Our patient's phenotype included
prominent forehead, midface hypoplasia, intermittent
strabismus, low set ears, carp-shaped mouth, retrog-
nathia, coarctation of the aorta, partial agenesis of corpus
callosum, and mild to moderate developmental delay.
Two patients with interstitial deletion of 15q15q21 have
also been described with craniosynostosis [7,9]. Neuro-
logical problems including hypotonia and seizures are
also seen in many individuals with the deletion of this
region of chromosome 15q. Congenital heart defect with
septal hypertrophy and dilatation of the aorta and pulmo-
nary artery was described in one patient with the deletion
of 15q21q24 [5], who died at 8 months of age. Another
patient in the same report had deletion of 15q22q25 and
frequent cyanosis of the extremities with no heart mur-
mur, and died at 2 years of age with severe respiratory ill-
ness. Five other patients with comparable interstitial
deletion [[1-4,6] had no evidence of congenital heart dis-
ease. Two additional cases with interstitial deletion of
chromosome15q15-21 have been described with atrial
and ventricular septal defects and Tetralogy of Fallot with
septal hypertrophy, respectively [7,8]. We explored prob-
able hemizygous deletion of a cardiac specific gene within
the 15q21.1-q22.2 interval responsible for structural heart
defects in these individuals. Within this deletion interval,
there are few genes that are known to be expressed in
heart, including ARPP-19 [13], RAB27A [14], and
ADAM10 [15]. The α-tropomyosin gene, TPM1 maps to
15q22.2 and is located within the broader chromosome
15 deletion interval, as suggested by the G-band analysis.
Heterozygous point mutations in TPM1, account for <5%
cases of familial hypertrophic cardiomyopathy [16]. The
phenotype ranges from a benign course to severe hyper-
trophy with progression to dilated cardiomyopathy
[16,17]. In view of our patient's cardiac phenotype, which
included septal hypertrophy and juxtaductal aortic coarc-
tation, TPM1 appeared a good candidate gene to investi-
gate if it was included within the deleted region. Prior to
performing the array-CGH, we carried out FISH with
RP11-69G7 encompassing the TPM1 gene (Figure 3). We
established that TPM1 was not included within the dele-
tion interval and ruled out the deletion of TPM1 gene
causing left ventricular outflow tract obstruction observed
in this patient. The array-CGH subsequently confirmed
that RP11-69G7 maps approximately 4 Mb distal to RP11-
50C13, the most telomeric clone deleted on the array-
CGH in our patient.
Conclusion
The array CGH refined the interstitial deletion in our
patient to 15q21.1-q22.2. Microarray-based Comparative
genomic hybridization is a powerful method to detect and
analyze genomic imbalances. Array CGH using large
insert clones is a very useful tool for detecting microdele-
tions or duplications that are well below the level of detec-
tion on high resolution banded karyotype analysis. We
have used chromosome 15-specific microarray to define
the 15q breakpoints in this case, thus providing a better
opportunity for genotype/phenotype correlations in other
similarly affected individuals.
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